Drug Profile
Research programme: target-specific catalytic metallodrug therapeutics - MetalloPharm
Latest Information Update: 28 Sep 2020
Price :
$50
*
At a glance
- Originator MetalloPharm
- Class Antibacterials; Antineoplastics; Antivirals; Cardiovascular therapies; Metals
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Bacterial infections; Cancer; Cardiovascular disorders; Viral infections
Highest Development Phases
- No development reported Bacterial infections; Cancer; Cardiovascular disorders; Viral infections
Most Recent Events
- 28 Sep 2020 No recent reports of development identified for research development in Bacterial-infections in USA
- 28 Sep 2020 No recent reports of development identified for research development in Cancer in USA
- 28 Sep 2020 No recent reports of development identified for research development in Cardiovascular-disorders in USA